Abstract
Aims: Antiviral-drug-resistance is a common phenomenon in chronic hepatitis B therapy. Lamivudine-resistant mutants are mostly sensitive to the nucleoside analogue adefovir dipivoxil. Adefovir-resistant mutants are rare and retain sensitive to lamivudine. Patients with cirrhosis and precore mutant infection have an increased risk for exacerbation of liver disease due to drug-resistance. Viral resistance against both drugs is an indication for switching treatment to experimental antiviral regimes. Main therapeutic need is to prevent virological failure as well as to reach sufficient viral suppression before liver transplantation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
